James Kirkland

James Kirkland led the first clinical trials of senolytic drug combinations, demonstrating that dasatinib plus quercetin can selectively eliminate senescent cells in humans with measurable reduction of SASP markers. His laboratory identified the dasatinib plus quercetin combination as a potent senolytic regimen through systematic screening of anti-apoptotic pathway dependencies in senescent cells. He advanced fisetin as a natural senolytic compound with cancer-preventive potential now in multiple clinical trials. His geroscience approach connecting aging biology to cancer prevention represents a paradigm shift in oncology.